What is 20/20 Biolabs, Inc. Common Stock (AIDX) stock price today?

20/20 Biolabs, Inc. Common Stock (AIDX) currently trades at $1.49 per share. The stock has a market capitalization of $15.62M and a P/E ratio of —x.

Is AIDX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, 20/20 Biolabs, Inc. Common Stock has a Smart Value Score of 15/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is 20/20 Biolabs, Inc. Common Stock's revenue and earnings?

20/20 Biolabs, Inc. Common Stock has trailing twelve-month (TTM) revenue of $2.05M with profit margins of -182.80%. Earnings per share (EPS) is $-0.36.

AIDX

20/20 Biolabs, Inc. Common Stock

NASDAQ: AIDX · HEALTHCARE · MEDICAL DEVICES

$1.49

-1.97% today

Updated 2026-05-05

Market cap

$15.62M

P/E ratio

—

P/S ratio

7.64x

EPS (TTM)

$-0.36

Dividend yield

—

52W range

$1 – $50

Volume

0.2M

Market cap

$15.62M

P/E ratio

—

P/S ratio

7.64x

EPS (TTM)

$-0.36

Dividend yield

—

52W range

$1 – $50

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.0

Growth

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →197 stocks currently score above 75

Price targets

Analyst target

$—

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at -182.80%

- Negative free cash flow $-511667.00

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$11.06M	$1.42M	$1.75M	$2.05B	$2.05M
Net income	$2.19M	$-6.39M	$-5.55M	$-3.74B	$-1.31M
EPS	—	—	—	—	$-0.36
Free cash flow	$5.54M	$-4.64M	$-2.60M	$-1.92B	$-511667.00
Profit margin	19.77%	-448.73%	-316.81%	-182.82%	-182.80%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AIDX	$15.62M	15	6.0	2.0	5.0	5.0	—	Avoid
LLY	$862.01B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$546.90B	59	4.7	9.0	3.3	6.0	-40.34%	Buy
ABBV	$365.43B	63	4.0	8.0	4.0	5.0	-22.55%	Buy
UNH	$336.72B	54	5.3	5.5	7.3	4.8	+43.12%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+3.99%	Buy

Smart narrative

20/20 Biolabs, Inc. Common Stock trades at $1.49. Our Smart Value Score of 15/100 indicates the stock is weak. TTM revenue stands at $2.05M. with profit margins at -182.80%.

Frequently asked questions

What is 20/20 Biolabs, Inc. Common Stock's stock price?

20/20 Biolabs, Inc. Common Stock (AIDX) trades at $1.49.

Is 20/20 Biolabs, Inc. Common Stock overvalued?

Smart Value Score 15/100 (Grade F, Strong Sell).

What is the price target of 20/20 Biolabs, Inc. Common Stock (AIDX)?

The analyst target price is $—, representing NaN% downside from the current price of $1.49.

What is 20/20 Biolabs, Inc. Common Stock's revenue?

TTM revenue is $2.05M.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7.64x

ROE-503.00%

Beta-0.43

50D MA$2.47

200D MA$3.12

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

AIDX vs LLY →AIDX vs JNJ →AIDX vs ABBV →Stock screener →